A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab and Bevacizumab

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer »